UC Medical Center Recertified as Advanced Stroke Care Center
University of Cincinnati (UC) Medical Center has again earned The Joint Commissions Advanced Certification for Comprehensive Stroke Centers, the highest level of certification reserved for institutions with specific abilities to receive and treat the most complex stroke cases.
- The UC Stroke Team, founded as the first multidisciplinary stroke team in the U.S. during the mid-1980s, provides stroke evaluation for acute stroke therapy around the clock at 15 regional hospitals, as well as consultation at over 20 other regional hospitals.
- In 2012, the UC Gardner Neuroscience Institute and UC Medical Center launched a major initiative to bring the expertise of the UC Stroke Team to partner hospitals through telestroke, the use of telemedicine specifically for stroke care.
- UC researchers played a leading role in developing and testing the clot-busting drug tissue plasminogen activator, or tPA, to treat acute ischemic stroke. Such a stroke occurs when an artery to the brain is blocked, typically by a blood clot. Intravenous tPA is the only FDA-approved medical treatment for stroke caused by a blood clot.
- UC is the National Coordinating Center for the NIH-funded StrokeNet, a network of major research hospitals across the country conducting state-of-the-art stroke research in prevention, treatment and recovery.
- UC researchers also direct neurorecovery/neuroimaging studies in stroke recovery, participate in the major medical and surgical prevention studies and have an active translational laboratory studying preclinical models of stroke and cerebrovascular disease.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.